目的 对现有间变性淋巴瘤激酶-酪氨酸激酶抑制剂（ALK-TKIs）类药物用于晚期非小细胞肺癌进行量化的临床综合评价，以期为遴选此类药物提供参考依据。方法 基于《中国医疗机构药品评价与遴选快速指南（第二版）》，从药学特性、有效性、安全性、经济性和其他属性5个方面对ALK-TKIs进行评估和评分。结果 超过70分的药物从高到低依次为阿来替尼、洛拉替尼、克唑替尼、布格替尼和塞瑞替尼，其中阿来替尼超过80分。恩沙替尼、伊鲁阿克和依奉阿克得分在60～70分。结论 阿来替尼、洛拉替尼、克唑替尼、布格替尼和塞瑞替尼为强烈推荐，恩沙替尼、伊鲁阿克和依奉阿克为弱推荐或暂时保留，此外还需依照医疗机构实际情况遴选合适的药物。

Objective To conduct a quantitative and comprehensive clinical evaluation of the existing class of anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) for advanced non-small-cell lung cancer, with the aim of providing a reference basis for the selection of such drugs. Methods Based on “the Rapid Guide for Drug Evaluation and Selection in Chinese Medical Institutions (Second Edition)”, ALK-TKIs were evaluated and scored in terms of five aspects, namely, pharmacological properties, efficacy, safety, economy and other attributes. Results The drugs with a score over 70, from high to low, are alectinib, loratinib, crizotinib, brigatinb and ceritinib, among which alectinib has a score over 80. Ensatinib, iruplinalkib and envonalkib scored between 60 and 70 points. Conclusion Alectinib, loratinib, crizotinib, brigatinb and ceritinib are strongly recommended, while ensatinib, iruplinalkib and envonalkib are weakly recommended or temporarily retained. In addition, the appropriate drugs should be selected based on the actual situation of the medical institution.

R979.1

吴阶平医学基金会药物治疗专项（320.6750.2025-18-65）